Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05453591 | Investigation of Urinary Biomarkers for the Detection of Breast Cancer(URODETECT-WP3) | unknown | N/A | 200 | Novosanis NVINDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05781633 | The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer. | unknown | N/A | 43 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 23, 2023 |
| clinicaltrials |
| NCT05782504 | Patient-centered Breast Cancer Teleprehabilitation(BC-PREHAB) | unknown | N/A | 50 | Universitair Ziekenhuis BrusselOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT00470236 | Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast(DCIS) | unknown | N/A | 1,608 | Trans Tasman Radiation Oncology GroupOTHER | 11 | Mar 22, 2023 | clinicaltrials |
| NCT05456373 | Intraoperative Use of ClearEdge Device in Breast Conserving Surgery | unknown | N/A | 288 | LS BioPathINDUSTRY | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05633342 | Project CADENCE (CAncer Detected Early caN be CurEd)(CADENCE) | unknown | — | 15,000 | MiRXES Pte LtdINDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05775575 | A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer | unknown | Phase 1 / Phase 2 | 65 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04924699 | A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer | unknown | Phase 2 / Phase 3 | 350 | Shanghai Miracogen Inc.INDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05072197 | Mobile Application Support for Women With Breast Cancer Undergoing Chemotherapy | unknown | N/A | 70 | Cheng-Hsin General HospitalOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05771337 | Circular RNA and Chemerin in Breast Cancer Patient | unknown | — | 80 | Assiut UniversityOTHER | 0 | Mar 16, 2023 | clinicaltrials |
| NCT05769491 | Looking At Triple Negative Breast Cancer Patient Experience Patterns in Medical Trials | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Mar 15, 2023 | clinicaltrials |
| NCT04778670 | Artificial Intelligence in Large-scale Breast Cancer Screening(ScreenTrustCAD) | unknown | N/A | 55,579 | Karolinska University HospitalOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05767931 | Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer | unknown | — | 60 | Peking UniversityOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05768451 | Ultrasound Radiomics for Predicting Breast Cancer and Axillary Lymph Node Metastasis | unknown | — | 200 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Mar 14, 2023 | clinicaltrials |
| NCT05633680 | Circulating Tumor Cells Screen for Breast Cancer(CTCSFBC) | unknown | — | 200 | Handan First HospitalOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT05765916 | An Online Psychosocial Intervention for Fear of Cancer Recurrence in Breast Cancer Survivors | unknown | N/A | 244 | National University of SingaporeOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT05515289 | Study of SHR6390 in Renal Insufficiency and Healthy Subjects | unknown | Phase 1 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05763472 | Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation(Gen-eva) | unknown | — | 10 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT04365790 | Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma | unknown | — | 500 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT04403984 | Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes | unknown | — | 750 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05754060 | Cognitive Processing Slowness as a Marker of Cognitive Impairment in Non-central Nervous System Cancer Patients(RIVAGE) | unknown | — | 200 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Mar 8, 2023 | clinicaltrials |
| NCT05760222 | Acupuncture Treatment of Vasomotor Symptoms in Breast Cancer Patients(Acu-HOTFLASH) | unknown | N/A | 90 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03772353 | Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer(PLEASURABLE) | unknown | Phase 1 / Phase 2 | 59 | Fudan UniversityOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT05628077 | Prevalence and Risk Factors for Pain and Related Adverse Reactions Among Breast Cancer Survivors on Aromatase Inhibitors | unknown | — | 1,200 | Peking University People's HospitalOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT03412643 | Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling(FB-12) | unknown | Phase 2 | 64 | NSABP Foundation IncNETWORK | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05753865 | A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound) | unknown | Phase 3 | 454 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05750693 | PIK3CA in HER2+ BC and pCR Trial | unknown | N/A | 58 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT04942899 | Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer | unknown | Phase 2 | 70 | Assiut UniversityOTHER | 0 | Mar 1, 2023 | clinicaltrials |
| NCT05749016 | Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer | unknown | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05749575 | Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer. | unknown | Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05670925 | A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC. | unknown | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05747313 | Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05747326 | Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer | unknown | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04846972 | Facilitate and Sustain Return to Work After Breast Cancer(FASTRACS-RCT) | unknown | — | 420 | Hospices Civils de LyonOTHER | 1 | Feb 27, 2023 | clinicaltrials |
| NCT05744518 | Monitoring Response to Neoadjuvant Chemotherapy in Breast Cancer Using Ultrafast DCE-MRI | unknown | — | 80 | Fudan UniversityOTHER | 1 | Feb 27, 2023 | clinicaltrials |
| NCT05649475 | Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy | unknown | — | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05743023 | Consciousness-based Ayurveda Lifestyle Program for Improving Quality of Life in Survivors of Breast Cancer | unknown | N/A | 15 | Robert Schneider, MDOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05417048 | Clinical Study of Glycosylated Extracellular Vesicles for Early Diagnosis of Breast Cancer | unknown | — | 420 | Peking UniversityOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05728632 | Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines(CONTROL) | unknown | Phase 3 | 80 | Giulio StefaniniOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT04226222 | Bringing of PET-TDM FDG in the Determination of the Characteristics of Primary Mammary Tumors TrIple Negatives(FICTION) | unknown | — | 132 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04997798 | Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05430347 | Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer | unknown | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05733026 | Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Doxorubicin Among Egyptian Breast Cancer Patients | unknown | — | 200 | Ain Shams UniversityOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT05386524 | Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02983071 | G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 4 | Feb 15, 2023 | clinicaltrials |
| NCT04857229 | Histolog Comparison to Standard Histology(HiCoSH) | unknown | — | 101 | Imperial College LondonOTHER | 1 | Feb 14, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Mar 24, 2023source: clinicaltrials